The end of the line for neutrophils
In this issue of Blood, Bartels and colleagues demonstrate that acetylation of the transcription factor CCAAT enhancer binding protein e (C/EBPe) is essential for terminal neutrophil granulocyte differentiation.
1 N eutrophils, the most abundant granulocytes, are essential for host innate immune defense. Neutropenia results from damage to the bone marrow or depletion or destruction of neutrophils by drugs, diseases, or congenital disorders that block neutrophil differentiation. Neutropenic individuals are extremely susceptible to bacterial infection, and febrile neutropenia increases the risk of mortality in cancer patients receiving myelosuppressive chemotherapy. 2 Prophylactic use of granulocyte colonystimulating factor (G-CSF) reduces mortality by increasing neutrophil numbers. 2 A better understanding of the mechanisms that regulate granulopoiesis and terminal neutrophil differentiation could spur development of new strategies to overcome neutropenia and improve clinical outcomes. The C/EBP transcription factor family is essential for granulopoiesis and terminal differentiation of neutrophils.
3 C/EBPa is predominantly expressed in immature myeloid cells, and lack of expression leads to a block at the myeloblast stage. 3 C/EBPb is expressed from the metamyelocyte stage and on during maturation. 3 C/EBPb-deficient mice display normal granulocyte differentiation and steadystate levels of neutrophils but are unable to produce neutrophils in response to cytokine
Acetylation of C/EBPe is essential for terminal neutrophil differentiation and function. C/EBPe is acetylated during granulocytic differentiation toward neutrophils by lysine acetylases (KAC, eg, p300) or lysine deacetylase inhibitors (KDACi, eg, nicotinamide inhibiting KDAC SIRT1). Acetylation on K121 and K198 is essential for terminal differentiation of neutrophils and expression of secondary granule proteins. Differential acetylation of C/EBPe could be important for determining differentiation along the neutrophil or eosinophil lineages.
exposure or infection during "emergency" granulopoiesis. 4 C/EBPe is expressed at the promyelocyte to myelocyte stage, and knockout mice lack neutrophils and eosinophils because of a block at this stage. 3 Interestingly, mutations in the CEBPE gene account for some cases of human neutrophil-specific granule disease, a rare congenital disorder, characterized by increased circulating, immature neutrophils, and recurrent pyogenic infections. 5 Also, induction of C/EBPe by G-CSF is important for inducing neutrophil maturation. 6 Expression of C/EBPe is restricted primarily to the myeloid lineage in 4 protein isoforms of 32, 30, 27, and 14 kDa. C/EBPe 32/30 activates transcription, C/EBPe 27 represses transcription, and C/EBPe 14 acts as a dominant negative. 1 The contribution of these different isoforms toward granulocytic differentiation remains largely unknown as is the importance of posttranslational modifications. Phosphorylation, sumoylation, and acetylation modulate the transcriptional activities of several C/EBP family members. C/EBPa is phosphorylated at several sites, and depending on the amino acid residue that is phosphorylated, granulocyte differentiation can be either blocked or increased. Also, sumolyation of lysine residues in C/EBPa inhibits granulocyte gene expression. 7 Acetylation of C/EBPb is functionally linked to transcriptional activity, but its impact on granulopoiesis is unknown. 1 Phosphorylation of C/EBPe on threonine 75, which is located in the transactivation domain, leads to increased DNA binding and transcriptional activity, and sumolyation of a lysine residue 121 (K121) within repression domain I enhances transcriptional activation by C/EBPe.
1
A potential role for acetylation in regulating neutrophil production and differentiation was suggested by these authors as lysine deacetylase inhibitors (KDACi) affect myeloid differentiation. 8 Skokowa et al demonstrated that nicotinamide phosphoribosyltransferase (NAMPT) mediates G-CSF-triggered granulopoiesis by increasing activity levels of the lysine deacetylase (KDAC) sirtuin 1 (SIRT1), levels of C/EBPa and -b, and expression of G-CSF and G-CSF receptor in vitro through the production of NAD The current study extends these findings and provides the first experimental evidence that acetylation at specific lysines (K121 and K198) is essential for C/EBPe 32/30 transcriptional activity and terminal differentiation of neutrophils (see figure) . One conclusion could be that acetylation at these lysines is selectively important for differentiation along either the neutrophil or eosinophil lineages (see figure) . 1 A limitation of the current study is that the conclusions are based on in vitro experiments. Future studies in a mouse model could provide more definitive evidence that acetylation of C/EBPe is essential during granulopoiesis in vivo. For example, one could introduce loss of function (K to A) or gain of function (K to Q , an "acetylation mimic") mutations in the endogenous Cebpe gene by genome editing and determine the impact on terminal neutrophil differentiation. Prior studies with nicotinamide suggest a potentially important function for acetylation of C/EBP members in boosting neutrophil numbers and function.
9,10 The current study's novel findings provide for the first time the important experimental evidence that acetylation of C/EBPe is critical for terminal neutrophil differentiation. These findings establish a foundation for future work toward developing therapies that more effectively and specifically manipulate neutrophil production and function with the goal of treating neutropenia and neutrophil dysfunction. Conflict-of-interest disclosure: The author declares no competing financial interests. n In this issue of Blood, Kapur et al show that C-reactive protein (CRP) enhances IgG-mediated phagocytosis of platelets and patients with immune thrombocytopenia (ITP) have elevated CRP levels, which predicted slower platelet recoveries and bleeding severity. 2 In FNAIT, for example, the antiplatelet IgG antibodies cross the placenta and target the fetal platelets, which can result in serious complications such as intracerebral hemorrhage. Antibody titer has been shown to be related to fetal platelet counts 3 ; however, this correlation is far from perfect, as there are many cases not attributed to antibody titer alone, 4 suggesting other factors such as IgG Fc-fucosylation may be involved. 5 Even more striking, in ITP, there is no test that reliably predicts bleeding outcomes or severity of bleeding. Thus, a tool for the prediction of both FNAIT and ITP severity is highly warranted. Kapur et al describe a series of elegant studies in which a serum factor was found to enhance IgG-mediated responses (respiratory burst and phagocytosis) against platelets. 1 The involvement of the complement cascade was excluded, and the factor was found to be present in healthy sera and appeared to be acting against platelets in a calcium-dependent manner. As such, CRP was convincingly identified as the serum factor that enhanced IgG-mediated phagocytosis of platelets.
CRP belongs to the pentraxin family, which contains a calcium-dependent ligand binding site and is a major acute-phase protein and a known ligand for FcRs. 6 CRP is significantly upregulated during infections (from ,0.05 to .500 mg/L), but is also present in healthy sera, albeit at a lower concentrations (;0.8 mg/L in healthy adult volunteers). 6 There was an intriguing correlation between CRP concentrations in 14 different healthy sera and antibody-mediated phagocytic activity against platelets. 1 In addition, purified CRP was clearly shown to enhance antibodymediated phagocytic responses against platelets, and CRP depletion and repletion experiments corresponded to IgG-mediated phagocytic activity against platelets. Several experiments were performed to elucidate the working mechanism of CRP in IgG-mediated targeting of platelets. Platelet activation was shown to be involved, but not via the platelet FcgRIIa. Using pneumococcal cell wall polysaccharide (CWPS), which binds to the phosphorylcholine-ligand binding site on CRP, the authors demonstrated an abrogation of the IgG-enhancing serum effect in a phagocytic assay. Furthermore, using a novel innovative approach of cellular surface plasmon resonance, CRP binding to platelets was further explored. CRP was absorbed on sensor surface spots on a chip and IgG-opsonized platelets were circulated over the chip, measuring the specific interaction of platelets to CRP with high sensitivity. IgG-opsonized platelets demonstrated increased binding to CRP compared with isotype control (nonbound) platelets. Importantly, the binding of platelets to CRP was completely blocked by coinjection of CWPS, suggesting that CRP binds to platelet-membrane phosphorylcholine exposed after platelet activation induced by the antiplatelet antibodies. The nature of this platelet activation was further explored by using both inhibitors and an enhancer of oxidation. Platelet oxidation was found to be associated with increased binding to CRP and, using oxidation inhibitors in the platelet phagocytosis assay, the authors additionally demonstrated a role for the phagocyte reduced NAD phosphate (NADPH) oxidase system.
The aforementioned experiments were conducted with antibodies from maternal FNAIT sera (anti-HPA-1a antibodies), as well as a human monoclonal FNAIT antibody, B2G1. As CRP levels were found to be Binding of antiplatelet antibodies (Ab) to platelets (Plt) triggers platelet oxidation, which also requires the phagocyte NADPH oxidase system. Platelet oxidation exposes oxidized phosphorylcholine (Ox PC) residues from the platelet membrane, providing a Ca 21 -dependent binding platform for CRP. CRP subsequently boosts antibody-mediated platelet phagocytosis via phagocytic FcRs. The figure is based on Figure 7 in the article by Kapur et al that begins on page 1793.
